|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EAF2 |
Gene summary for EAF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EAF2 | Gene ID | 55840 |
| Gene name | ELL associated factor 2 | |
| Gene Alias | BM040 | |
| Cytomap | 3q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q96CJ1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55840 | EAF2 | LZE4T | Human | Esophagus | ESCC | 1.02e-02 | 2.00e-01 | 0.0811 |
| 55840 | EAF2 | LZE20T | Human | Esophagus | ESCC | 1.48e-05 | 2.18e-01 | 0.0662 |
| 55840 | EAF2 | LZE24T | Human | Esophagus | ESCC | 1.56e-18 | 5.12e-01 | 0.0596 |
| 55840 | EAF2 | P1T-E | Human | Esophagus | ESCC | 1.24e-07 | 4.25e-01 | 0.0875 |
| 55840 | EAF2 | P2T-E | Human | Esophagus | ESCC | 9.50e-05 | 4.91e-02 | 0.1177 |
| 55840 | EAF2 | P4T-E | Human | Esophagus | ESCC | 3.69e-07 | 1.34e-01 | 0.1323 |
| 55840 | EAF2 | P8T-E | Human | Esophagus | ESCC | 5.24e-20 | 4.62e-01 | 0.0889 |
| 55840 | EAF2 | P9T-E | Human | Esophagus | ESCC | 3.32e-04 | 1.20e-01 | 0.1131 |
| 55840 | EAF2 | P10T-E | Human | Esophagus | ESCC | 4.97e-13 | 1.93e-01 | 0.116 |
| 55840 | EAF2 | P11T-E | Human | Esophagus | ESCC | 7.47e-04 | 2.00e-01 | 0.1426 |
| 55840 | EAF2 | P15T-E | Human | Esophagus | ESCC | 3.50e-09 | 1.92e-01 | 0.1149 |
| 55840 | EAF2 | P16T-E | Human | Esophagus | ESCC | 1.51e-02 | 7.17e-02 | 0.1153 |
| 55840 | EAF2 | P20T-E | Human | Esophagus | ESCC | 4.77e-10 | 1.98e-01 | 0.1124 |
| 55840 | EAF2 | P21T-E | Human | Esophagus | ESCC | 8.00e-03 | 1.07e-01 | 0.1617 |
| 55840 | EAF2 | P23T-E | Human | Esophagus | ESCC | 8.22e-13 | 3.34e-01 | 0.108 |
| 55840 | EAF2 | P26T-E | Human | Esophagus | ESCC | 2.12e-05 | 1.16e-01 | 0.1276 |
| 55840 | EAF2 | P27T-E | Human | Esophagus | ESCC | 1.31e-05 | 1.51e-01 | 0.1055 |
| 55840 | EAF2 | P28T-E | Human | Esophagus | ESCC | 1.35e-04 | 7.40e-02 | 0.1149 |
| 55840 | EAF2 | P32T-E | Human | Esophagus | ESCC | 8.79e-04 | 7.32e-02 | 0.1666 |
| 55840 | EAF2 | P36T-E | Human | Esophagus | ESCC | 6.90e-03 | 1.16e-01 | 0.1187 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
| GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
| GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
| GO:000636814 | Esophagus | ESCC | transcription elongation from RNA polymerase II promoter | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
| GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
| GO:003278412 | Esophagus | ESCC | regulation of DNA-templated transcription, elongation | 45/8552 | 53/18723 | 3.64e-09 | 7.61e-08 | 45 |
| GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
| GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
| GO:003424312 | Esophagus | ESCC | regulation of transcription elongation from RNA polymerase II promoter | 28/8552 | 32/18723 | 1.02e-06 | 1.29e-05 | 28 |
| GO:00459267 | Esophagus | ESCC | negative regulation of growth | 148/8552 | 249/18723 | 7.88e-06 | 7.73e-05 | 148 |
| GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
| GO:00308506 | Esophagus | ESCC | prostate gland development | 32/8552 | 45/18723 | 4.87e-04 | 2.70e-03 | 32 |
| GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
| GO:00303085 | Esophagus | ESCC | negative regulation of cell growth | 108/8552 | 188/18723 | 7.46e-04 | 3.87e-03 | 108 |
| GO:00016559 | Esophagus | ESCC | urogenital system development | 177/8552 | 338/18723 | 7.51e-03 | 2.69e-02 | 177 |
| GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
| GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
| GO:00063547 | Oral cavity | OSCC | DNA-templated transcription, elongation | 63/7305 | 91/18723 | 4.86e-09 | 1.07e-07 | 63 |
| GO:004873220 | Oral cavity | OSCC | gland development | 226/7305 | 436/18723 | 2.78e-08 | 5.39e-07 | 226 |
| GO:00063686 | Oral cavity | OSCC | transcription elongation from RNA polymerase II promoter | 48/7305 | 69/18723 | 2.60e-07 | 4.05e-06 | 48 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EAF2 | SNV | Missense_Mutation | c.214N>G | p.Pro72Ala | p.P72A | Q96CJ1 | protein_coding | tolerated(0.08) | possibly_damaging(0.506) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| EAF2 | SNV | Missense_Mutation | novel | c.247N>G | p.Tyr83Asp | p.Y83D | Q96CJ1 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| EAF2 | SNV | Missense_Mutation | rs774441301 | c.296G>A | p.Arg99Gln | p.R99Q | Q96CJ1 | protein_coding | tolerated(0.39) | probably_damaging(0.989) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| EAF2 | SNV | Missense_Mutation | rs377108596 | c.295N>T | p.Arg99Trp | p.R99W | Q96CJ1 | protein_coding | tolerated(0.06) | probably_damaging(0.998) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| EAF2 | insertion | Frame_Shift_Ins | novel | c.236_237insA | p.Pro82ThrfsTer11 | p.P82Tfs*11 | Q96CJ1 | protein_coding | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| EAF2 | SNV | Missense_Mutation | novel | c.326N>A | p.Val109Glu | p.V109E | Q96CJ1 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A5-A0GW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EAF2 | SNV | Missense_Mutation | rs377108596 | c.295N>T | p.Arg99Trp | p.R99W | Q96CJ1 | protein_coding | tolerated(0.06) | probably_damaging(0.998) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EAF2 | SNV | Missense_Mutation | novel | c.579N>G | p.Ser193Arg | p.S193R | Q96CJ1 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| EAF2 | SNV | Missense_Mutation | rs373626345 | c.777N>G | p.Asp259Glu | p.D259E | Q96CJ1 | protein_coding | deleterious(0.03) | benign(0.013) | TCGA-AX-A06D-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
| EAF2 | SNV | Missense_Mutation | novel | c.631N>G | p.Asn211Asp | p.N211D | Q96CJ1 | protein_coding | tolerated(0.62) | benign(0.015) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |